STOCK TITAN
  1. Home
  2. News
  3. HSCS

HeartSciences Inc. - HSCS STOCK NEWS

Welcome to our dedicated page for HeartSciences news (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.

Heart Test Laboratories, Inc., operating under the brand name HeartSciences (symbol: HSCS), is an innovative company at the forefront of medical technology. Specializing in Artificial Intelligence (AI)-powered solutions, HeartSciences aims to revolutionize the field of cardiac screening by enhancing the capabilities of ECGs/EKGs. By leveraging advanced AI algorithms, the company focuses on the early detection of heart disease, making it a vital tool in frontline or point-of-care clinical settings.

HeartSciences' flagship product, the MyoVista® wavECG™, employs cutting-edge AI technology to provide a more comprehensive cardiac assessment, helping healthcare providers diagnose conditions that conventional ECGs might miss. This innovation has the potential to significantly improve patient outcomes by enabling earlier and more accurate detection of heart conditions.

Recently, HeartSciences announced the granting of an Indian patent for its MyoVista® Wavelet Technology, which underscores the company's commitment to expanding its global footprint. The company's ongoing projects include refining its AI algorithms and expanding the use of its technology in various clinical settings to further solidify its position as a leader in cardiac care.

In financial terms, HeartSciences continues to attract investor interest, exemplified by its listing on Nasdaq (HSCS; HSCSW). The company actively engages with its shareholders, as evidenced by the recent reminder for shareholders to vote ahead of the 2023 Annual Meeting of Stockholders, scheduled for January 17, 2024.

HeartSciences' commitment to innovation and improving healthcare is further demonstrated by data showing that their MyoVista AI-ECG model significantly outperformed traditional methods like NT-proBNP and ARIC HF score in screening for Stage B Heart Failure. This breakthrough indicates substantial progress in cardiac care and patient management.

For investors and stakeholders, HeartSciences provides regular updates and maintains transparent communication channels. The company encourages visits to its website and social media platforms for the latest news and developments.

News

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) announced the results of the 2024 Annual Meeting of Shareholders, including the passing of important resolutions and an adjournment in respect of Proposal 7. Approximately 54.37% of the Company’s outstanding shares were represented at the meeting. The shareholders approved the re-election of director nominees, the issuance of shares of common stock, the Equity Incentive Plan, the independent registered public accounting firm, and amendments to the Company’s Certificate of Formation. Proposal 7, which aimed to lower the quorum for future meetings, was adjourned until February 15, 2024 due to insufficient votes. The reconvened Annual Meeting will be held virtually, and shareholders are encouraged to vote by February 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
none
-
News

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Rhea-AI Summary
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) reminds shareholders to vote ahead of its 2023 Annual Meeting of Stockholders on January 17, 2024. All shareholders on record as of November 20, 2023, are entitled to participate and vote. Shareholders are encouraged to read the company’s definitive proxy statement on Schedule 14A, filed with the SEC on December 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
none
-
News

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) reported financial results for Q2 fiscal 2024, highlighting transformative changes through agreements with the Icahn School of Medicine at Mount Sinai, FDA confirmation for a standard 510(k) submission pathway, and expanded international distribution channels. The company also raised $9.6 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
earnings
News

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) has received FDA confirmation to change the clearance pathway for its MyoVista® wavECG™ device and associated AI-ECG algorithm to a more standard 510(k) submission from the De Novo process. The company aims to deliver innovative AI-ECG diagnosis from millions of existing ECG devices worldwide and is on track for FDA submission in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
-
News

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

Rhea-AI Summary
Heart Test Laboratories, Inc. (Nasdaq: HSCS; HSCSW) announced the closing of license agreements with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) to develop and commercialize electrocardiographic AI algorithms and assets. The licenses result in Icahn Mount Sinai becoming a shareholder in the company. HeartSciences aims to bring new AI-powered ECG capabilities to market, enabling the early detection of heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.45%
Tags
AI
-
News

HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Rhea-AI Summary
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd to be used in its heart screening program for the Association of Garda Sergeants and Inspectors. Cardiact has placed an initial order for 2,400 patient tests and established a new referral pathway directly to cardiology. This announcement follows recent positive developments, including agreements with Icahn School of Medicine at Mount Sinai and the creation of a new FDA product classification for AI-ECG algorithms, positioning AI-ECG as a transformative tool for early heart disease detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
News

HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

Rhea-AI Summary
HeartSciences announces transformative agreements with Icahn Mount Sinai and files FDA Pre-Submission Request
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
News

HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio

Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, has been issued new patents in Brazil and the UAE, bringing its total patent portfolio to 33 international patents and 9 US patents. CEO Andrew Simpson expects AI to drive significant growth in the ECG market to $25 billion per year by 2032. HeartSciences also recently signed agreements with Mount Sinai to expand its cardiovascular disease screening capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
none
-
News

HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.

Rhea-AI Summary
HeartSciences CEO to present at Maxim Group's Virtual Tech Conference Series: Emerging Growth in A.I.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
conferences acquisition
News

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

Rhea-AI Summary
HeartSciences partners with Icahn Mount Sinai to commercialize AI algorithms for cardiovascular disease detection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none

FAQ

What is the current stock price of HeartSciences (HSCS)?

The current stock price of HeartSciences (HSCS) is $3.83 as of December 20, 2024.

What is the market cap of HeartSciences (HSCS)?

The market cap of HeartSciences (HSCS) is approximately 3.1M.

What is HeartSciences' primary focus?

HeartSciences focuses on using AI technology to transform ECGs/EKGs for the early detection of heart disease.

What is the MyoVista® wavECG™?

The MyoVista® wavECG™ is HeartSciences' flagship product that employs AI to provide comprehensive cardiac assessments.

When is the next Annual Meeting of Stockholders?

The next Annual Meeting of Stockholders is scheduled for January 17, 2024.

What recent patent has HeartSciences been granted?

HeartSciences was recently granted an Indian patent for its MyoVista® Wavelet Technology.

How does the MyoVista AI-ECG compare to traditional methods?

The MyoVista AI-ECG model significantly outperformed traditional methods like NT-proBNP and ARIC HF score in screening for Stage B Heart Failure.

Where can I find the latest updates about HeartSciences?

You can find the latest updates on HeartSciences' website and their social media platforms.

What stock exchange is HeartSciences listed on?

HeartSciences is listed on Nasdaq under the symbols HSCS and HSCSW.

What is the significance of HeartSciences' AI technology?

HeartSciences' AI technology enhances the diagnostic capabilities of ECGs/EKGs, leading to earlier and more accurate detection of heart conditions.

Who can participate in the upcoming Annual Meeting of Stockholders?

All shareholders on record of HeartSciences' outstanding shares of common stock and preferred stock as of November 20, 2023, are entitled to participate and vote.

How does HeartSciences engage with its shareholders?

HeartSciences maintains transparent communication and encourages shareholders to participate in meetings and stay informed through regular updates on their website and social media.

Stock HSCS logo
HeartSciences Inc.

Nasdaq:HSCS

HSCS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

HSCS Stock Data

3.15M
883.13k
10.64%
1.43%
3.33%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
SOUTHLAKE